ArticlePakistan journal of medical sciences2026
Suprachoroidal Triamcinolone Plus Intravitreal Bevacizumab Versus Bevacizumab Alone for Diabetic Macular Edema in Pseudophakic Eyes: A randomized controlled trial.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the efficacy of intravitreal bevacizumab (IVB) monotherapy versus a combination of IVB and suprachoroidal triamcinolone acetonide (SCTA) followed by monthly IVB in pseudophakic eyes with center-involving diabetic macular edema (DME). Methodology: The Ophthalmology Department of Khyber Teaching Hospital conducted this randomized controlled study between April 2023 to February 2024. Eighty-two pseudophakic patients with center-involving DME were randomly divided into two groups (41 each). The monotherapy group (Group-I) received a monthly injection of IVB (1.25mg/0.05 mL) for three months. The combination therapy group (Group-II) received combination of IVB (1.25 mg/0.05 mL) and SCTA (4 mg/0.1 mL) injections at first visit which were then followed by monthly IVB injection for next two months. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at baseline and at four months. Results: Both groups showed statistically significant improvement in BCVA and CMT from baselines. In Group-I, BCVA improved from 0.90±0.31 to 0.69±0.31 (p<0.001), and CMT decreased from 385.12±68.51 µm to 329.22±55.70 µm (p<0.001). In Group-II, BCVA improved from 0.84±0.28 to 0.52±0.21 (p<0.001), while CMT decreased from 382.49±63.32 µm to 292.46±32.24 µm (p<0.001). When compared between the groups, Group-II showed statistically significant improvement both in BCVA (p=0.034) and CMT (p<0.001). Conclusion: In pseudophakic patients with center-involving DME, a single combined treatment with SCTA and IVB yields better anatomical response and visual improvements as compared to IVB monotherapy. This combination approach might provide more therapeutic efficacy in terms of reducing macular edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.